EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study

Dima Kabbani, Demitra M Yotis, Victor H Ferreira, Sarah Shalhoub, Sara Belga iD, Varalika Tyagi, Matthew Ierullo, Vathany Kulasingam, Marie-Josée Hébert, Lori West, Jean-Sébastien Delisle, Normand Racine und 5 weitere

Open Forum Infectious Diseases · 03.05.2023 · 10 (5)

DOI: 10.1093/ofid/ofad200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 13.04.2023. Verfasst von Dima Kabbani und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Public Health Agency of Canada, COVID-19 Immunity Task Force, Vaccine Surveillance Reference Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Solid organ transplant (SOT) recipients are at risk for severe coronavirus disease 2019 (COVID-19), despite vaccination. Our study aimed to elucidate COVID-19 vaccine immunogenicity and evaluate adverse events such as hospitalization, rejection, and breakthrough infection in a SOT cohort.

Methods

We performed a prospective, observational study on 539 adult SOT recipients (age ≥18 years old) recruited from 7 Canadian transplant centers. Demographics including transplant characteristics, vaccine types, and immunosuppression and events such as hospitalization, infection, and rejection were recorded. Follow ups occurred every 4–6 weeks postvaccination and at 6 and 12 months from first dose. Serum was processed from whole blood to measure anti-receptor binding domain (RBD) antibodies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to assess immunogenicity.

Results

The COVID-19 vaccines were found to be safe in SOT recipients with low rates of rejection requiring therapy (0.7%). Immunogenicity improved after the third vaccine dose, yet 21% developed no anti-RBD response. Factors such as older age, lung transplantation, chronic kidney disease, and shorter duration from transplant were associated with decreased immunogenicity. Patients with at least 3 doses were protected from hospitalization when experiencing breakthrough infections. Significantly increased anti-RBD levels were observed in patients who received 3 doses and had breakthrough infection.

Conclusions

Three or four doses of COVID-19 vaccines were safe, increased immunogenicity, and protected against severe disease requiring hospitalization. Infection paired with multiple vaccinations significantly increased anti-RBD response. However, SOT populations should continue to practice infection prevention measures, and they should be prioritized for SARS-CoV-2 pre-exposure prophylactics and early therapeutics.

Schlagwörter

Stichwörter der Autor:innen

SARS-CoV-2solid organ transplantvaccines

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Canadian Donation and Transplantation Research Program (CDTRP), Edmonton, Alberta, Canada.
  • Transplant Infectious Diseases and Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
  • Division of Infectious Diseases, Department of Medicine, Western University, London, Ontario, Canada.
  • Division of Infectious Diseases, Department of Medicine, University of British Columbia, and Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.
  • Laboratory Medicine Program, University Health Network, University Health Network, University of Toronto, Ontario, Canada.

ORCID-Profile: Sara Belga

Förderung

  • Public Health Agency of Canada
  • COVID-19 Immunity Task Force
  • Vaccine Surveillance Reference Group
  • FRQS Pandemic Initiatives COVID-19

Zitieren

APA

Kabbani, D., Yotis, D. M., Ferreira, V. H., Shalhoub, S., Belga, S., Tyagi, V., Ierullo, M., Kulasingam, V., Hébert, M. J., West, L., Delisle, J. S., Racine, N., De Serres, S. A., Cardinal, H., Dieudé, M., Humar, A., & Kumar, D. (2023). Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study. Open Forum Infectious Diseases, 10(5). https://doi.org/10.1093/ofid/ofad200

Vancouver

Kabbani D, Yotis DM, Ferreira VH, Shalhoub S, Belga S, Tyagi V, et al. Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study. Open Forum Infectious Diseases. 2023;10(5). doi:10.1093/ofid/ofad200

BibTeX
@article{Kabbani2023,
  author = {Kabbani, Dima and Yotis, Demitra M and Ferreira, Victor H and Shalhoub, Sarah and Belga, Sara and Tyagi, Varalika and Ierullo, Matthew and Kulasingam, Vathany and Hébert, Marie-Josée and West, Lori and Delisle, Jean-Sébastien and Racine, Normand and De Serres, Sacha A and Cardinal, Héloïse and Dieudé, Mélanie and Humar, Atul and Kumar, Deepali},
  title = {Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study},
  journal = {Open Forum Infectious Diseases},
  year = {2023},
  volume = {10},
  number = {5},
  doi = {10.1093/ofid/ofad200}
}
Kostenlos starten →